For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study.
PURPOSE To determine the efficacy of sildenafil citrate ( Viagra ) in patients with erectile dysfunction after three-dimensional conformal external beam radiotherapy ( 3D-CRT ) for prostate cancer . METHODS AND MATERIAL S 406 patients with complaints of erectile dysfunction and who completed radiation at least 6 months before the study were approached by mail .  3D-CRT had been delivered ( mean dose 68 Gy ) . Sixty patients were included and entered a double-blind , placebo-controlled , cross-over study lasting 12 weeks . They received during 2 weeks 50 mg of sildenafil or placebo ; at Week 2 the dose was increased to 100 mg in case of unsatisfactory erectile response . At Week 6 , patients crossed over to the alternative treatment . Data were collected using the International Index of Erectile Function ( IIEF ) question naire , and side effects were recorded . RESULTS Mean age was 68 years . All patients completed the study . For most questions of the IIEF question naire there was a significant increase in mean scores from baseline with sildenafil , but not with placebo . Ninety percent of the patients needed a dose adjustment to 100 mg sildenafil .  Side effects were mild or moderate . CONCLUSION Sildenafil is well tolerated and effective in improving erectile function of patients with ED after 3D-CRT for prostate cancer
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .